Where Does CTI BioPharma Corp (CTIC) Stock Fall in the Biotechnology Field After It Is Higher By 3.33% This Week? InvestorsObserver
See the original post:
Where Does CTI BioPharma Corp (CTIC) Stock Fall in the Biotechnology Field After It Is Higher By 3.33% This Week? - InvestorsObserver
VIR BIOTECHNOLOGY, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K) Marketscreener.com
Continued here:
VIR BIOTECHNOLOGY, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K) - Marketscreener.com
Is Syndax Pharmaceuticals Inc (SNDX) Stock at the Top of the Biotechnology Industry? InvestorsObserver
Read more here:
Is Syndax Pharmaceuticals Inc (SNDX) Stock at the Top of the Biotechnology Industry? - InvestorsObserver
Jon Voight is 'blessed' to have had such a long Hollywood career Yakima Herald-Republic
Read more from the original source:
Jon Voight is 'blessed' to have had such a long Hollywood career - Yakima Herald-Republic
See more here:
USD Index to sink to 103 by end-2023 amid greater certainty and longevity of Dollar downtrend Westpac - FXStreet
- Data demonstrating that Ixo-vec was generally well tolerated and that a single intravitreal (IVT) injection can lead to stable and persistent aflibercept protein levels through three years in participants in the OPTIC extension study
See the original post:
Adverum Biotechnologies Presents Positive End of Study Results from the OPTIC Trial in Wet AMD Including Two-Year Outcomes Following a Single...
04.11.2022 at 18:30
Original post:
Orion Corporation: Acquisition of Own Shares 04.11.2022
ORION CORPORATION STOCK EXCHANGE RELEASE 4 NOVEMBER 2022 at 18.35 EET
Read this article:
Orion Corporation completed share acquisitions
SANTA ANA, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc., a biotechnology company harnessing the power of the body’s immune system through the development of natural killer (NK) cell therapies, today announced a collaboration with the Parkinson’s Foundation that will focus on ways to help accelerate NKGen’s clinical program using its novel autologous NK cell therapy (SNK01) for the treatment of advanced Parkinson’s disease (PD) through its network of clinical partners and donors.
View original post here:
NKGen Biotech Announces Collaboration with the Parkinson’s Foundation to Bring Its Novel Natural Killer Cell Therapy to the Clinic for Advanced...
VALNEVA
More here:
VALNEVA - Declaration of shares and voting rights: October 31, 2022
Leuven, BELGIUM, Boston, MA, US – November 4, 2022 – 7 PM CET Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, today announced that, pursuant to Belgian Transparency legislation1 it has received transparency notification following the issuance of new shares pursuant to the Capital Commitment entered into with Negma Group.Oxurion received a transparency notification from Fidelity Management & Research Company LLC, indicating that by virtue of a downward passive crossing of a threshold, its 3,128,819 common shares have crossed below the 5% threshold.
The rest is here:
Oxurion Receives Transparency Notification from Fidelity Management & Research Company LLC
Negma Group has converted 120 convertible bonds in Oxurion resulting in a EUR 300,000 capital increase. This is part of Negma Group’s EUR 30 million Capital Commitment1 that will allow Oxurion to focus on progressing its novel and differentiated back of the eye drug candidate targeting potential market opportunities of over USD 5 billion.
Read the original here:
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA
Bagsværd, Denmark, 4 November 2022 – This document discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
Link:
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
Webcast replay available at www.glpg.com
Read this article:
Galapagos presents roadmap for pipeline and commercial growth at its R&D Day 2022
SAN DIEGO, Nov. 04, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that the Company will present at the following upcoming investor conferences:
Link:
Fate Therapeutics to Present at Upcoming Investor Conferences
NDA Submission for Nyxol for RM and Initiation of VEGA-2 on Track for Q4 2022
See the original post:
Ocuphire Pharma Announces Financial Results for Third Quarter 2022 and Provides Corporate Update
Post hoc analysis of clinical data from the SCORED trial presented at the American Society of Nephrology Kidney Week 2022 annual scientific meeting, including evidence that:
Follow this link:
New Analysis of SCORED Trial Demonstrates Sotagliflozin’s Effect on Reducing Albuminuria in Patients With Type 2 Diabetes and Chronic Kidney Disease
- New analysis of cohort 7 data using a three-reader pathologist panel showed that 6/19 patients scored as having fibrosis stage 4 at baseline (putative F4); excluding these patients resulted in higher histological response rates in the patients with F2-F3 fibrosis than previously reported -
Read the original here:
89bio Presents Additional Exploratory Analyses from the Phase 1b/2a NASH Study of Pegozafermin at AASLD The Liver Meeting® 2022
CAMBRIDGE, Mass., Nov. 05, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, today presented additional interim results from an ongoing Phase 1 clinical trial of NTLA-2001, an investigational, in vivo CRISPR/Cas9 genome editing therapy in development as a single-dose treatment for transthyretin (ATTR) amyloidosis in collaboration with Regeneron Pharmaceuticals. Results were presented in a Late-Breaking Science oral presentation at the American Heart Association (AHA) Scientific Sessions 2022, held November 5 – 7 in Chicago, Illinois.
See original here:
Intellia Presents Updated Interim Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the...
Efficacy of OCA vs. placebo and external controls accepted as a late-breaker poster
Read the original post:
Intercept Announces Two Analyses Demonstrating Improvement in Outcomes, Including Transplant-Free Survival, for PBC Patients Treated with OCA to be...